<DOC>
	<DOCNO>NCT02978001</DOCNO>
	<brief_summary>The pathophysiological mechanism explain association psoriasis type 2 diabetes largely unknown hypothesize systemic inflammation find psoriasis type 2 diabetes might play role . In recent study hyperinsulinaemic euglycaemic clamp perform show normal glucose-tolerant patient moderate severe psoriasis lower whole-body insulin sensitivity insulin stimulation compare healthy match control . Thus , increase risk type 2 diabetes patient psoriasis appear include defect glucose metabolism link psoriasis . However , method apply allow detailed characterization metabolism patient psoriasis . Tracer technique combine indirect calorimetry never apply study hepatic whole body insulin sensitivity , glucose fat oxidation , basal condition insulin stimulation patient psoriasis . Aim study : The aim study investigate hepatic whole body insulin sensitivity glucose fat oxidation basal insulin-stimulated condition patient psoriasis .</brief_summary>
	<brief_title>Insulin Sensitivity , Glucose - Fat Metabolism Patients With Psoriasis</brief_title>
	<detailed_description>Background Psoriasis chronic immune-mediated inflammatory disease characterize uncontrolled proliferation keratinocytes , activate dendritic cell , release pro-inflammatory cytokine recruitment T-cells skin . The prevalence psoriasis 2-3 % worldwide , similar frequency men woman . Psoriasis associate component metabolic syndrome , particular obesity type 2 diabetes , patient psoriasis increase risk develop type 2 diabetes . Obesity twice prevalent patient psoriasis patient increase risk develop cardiovascular disease compare general population . These co-morbidities important recognize preferably prevent treat might lead increased mortality . Type 2 diabetes complex metabolic disorder develop consequence genetic environmental factor inadequate physical activity obesity . The incidence type 2 diabetes increase worldwide general agreement cause mainly adoption westernize , sedentary lifestyle . Patients type 2 diabetes characterize decreased peripheral hepatic insulin sensitivity , beta cell dysfunction impair glucose fat oxidation . Muscle insulin resistance propose account much 85-90 % impairment peripheral insulin sensitivity ( express total body glucose disposal ) patient type 2 diabetes insulin stimulation . Multiple intramyocellular defect demonstrate , include impair glucose transport phosphorylation , reduce glycogen synthesis , decrease glucose oxidation well proximal defect insulin signal transduction system . Similar psoriasis , systemic inflammation occur patient type 2 diabetes . The pathophysiological mechanism explain association psoriasis type 2 diabetes largely unknown hypothesize systemic inflammation find psoriasis type 2 diabetes might play role . In recent study hyperinsulinaemic euglycaemic clamp make show normal glucose-tolerant patient moderate severe psoriasis lower whole-body insulin sensitivity insulin stimulation compare healthy match control . Thus , increase risk type 2 diabetes patient psoriasis appear include defect glucose metabolism link psoriasis . However , method apply allow detailed characterization metabolism patient psoriasis . Tracer technique combine indirect calorimetry never apply study hepatic whole body insulin sensitivity , glucose fat oxidation , basal condition insulin stimulation patient psoriasis . Methods : Prior experimental day 1 2 participant meet morning follow 10 hour fast ( include liquid , medication , tobacco ) . No alcohol consumption vigorous physical activity permit 48 hour examination , participant request eat carbohydrate-rich diet previous two day . All experiment carry Center Diabetes Research , Gentofte Hospital , University Copenhagen , Hellerup , Denmark necessary equipment available . Experimental day 1 : An intravenous glucose tolerance test ( IVGTT ) , fibro scan liver perform second experimental day schedule . Time spent experimental day 1 approximately 4 hour . Intravenous glucose tolerance test ( IVGTT ) perform determine beta cell function . A glucose bolus 0.3 g/kg body weight infused 1 min t=0 min . Plasma sample glucose , C-peptide , insulin glucagon collect = -10 , - 5 , 0 , 2 , 4 , 6 , 8 , 10 , 15 , 20 30 min . Body composition determine prior Day 2 DXA scan ( Lunar Prodigy Advance GE Healthcare ) . Fibro scan perform use Fibroscan 501® ( EchoSensTM , Paris , France ) asses fibrosis status steatosis grade liver ( 23 ) . Hepatic elasticity thus fibrosis status ( express kPa ) assess measure transmission speed ultrasound base principle transmission speed vibration pass liver tissue increase hepatic fibrosis present . Hepatic steatosis assess control attenuation parameter ( CAP ) ( express decibel per meter ( dB/m ) ) base fact fat affect ultrasound propagation . A success rate ≥60 % ratio interquartile range liver stiffness median ≤30 % consider reliable use final analysis . Experimental day 2 : Hyperinsulinaemic euglycaemic clamp ( HEC ) combine stable isotope infusion , muscle fat biopsy indirect calorimetry . Time spent experimental day 1 approximately 7 hour . Following empty urine bladder , participant place recumbently bed . Two cannula insert cubital vein : one collection arterialize blood sample one contralateral vein infusion . The forearm blood sample draw wrap heat blanket ( 50°C ) throughout experiment . Immediately take background sample , prim constant infusion [ 6,6-D2 ] glucose ( D2-glucose ) ( prim bolus 40 µmol/kg ; continuous infusion rate 0.4 µmol· min·kg-1 ) [ 1,1,2,3,3 , -D5 ] glycerol ( D5-glycerol ) ( prim bolus 1.5 µmol/kg ; continuous infusion rate 0.1 µmol· min·kg-1 ) start ( t=0 min ) maintain 360 min determine glucose glycerol kinetics basal insulin-stimulated state , however continuous infusion rate change insulin infusion . The first steady-state period define last 30 min 120-min basal period , tracer equilibrium [ D2 ] glucose [ D5 ] glycerol expect ; low grade insulin infusion ( 10 mU/m2 per min ) steady-state period define last 30 min first insulin clamp period ( 210-240 min ) , infusion rate D2-glucose increase 0.56 µmol· min·kg-1 , infusion rate D5-glycerol reduce 0.05 µmol· min·kg-1 . The high grade insulin infusion ( 40 mU/m2 per min ) steady-state period define last 30 min second insulin clamp period ( 330-360 min ) , infusion rate D2-glucose increase 1.0 µmol· min·kg-1 , infusion rate D5-glycerol reduce 0.025 µmol· min·kg-1 . Following basal steady-state period time point 120 min , continuous insulin infusion initiate fixed 10 mU/m2 per min , infusion rate . At time point 240 min continuous insulin infusion prim raise 40 mU/m2 per min time point 360 min . A variable infusion unlabelled glucose ( 180 g/l ) use maintain euglycemia insulin infusion . Plasma glucose concentration monitor bedside every 5 min clamp use glucose oxidase method ( Yellow Springs Instrument Model 2300 STAT plus analyser , Yellow Springs , Ohio , USA ) . The target plasma glucose concentration 5 mM . Blood sample measure plasma glucose glycerol enrichment draw baseline ( 0 min ) first steady state period ( 90 , 100 , 110 120 min ) insulin-stimulated steady state period ( 330 , 340 , 350 360 min ) . All isotope purchase Cambridge Isotopes Laboratories ( Andover , MA ) . Blood sample measure plasma glycerol lactate drawn baseline first ( 90 120 min ) , second ( 210 240 min ) third ( 330-360 min ) steady-state period . Samples determine plasma insulin , C-peptide glucagon drawn ( 0 , 60 , 90 , 100 , 110 , 120 , 135 , 150 , 165 , 180 , 195 , 210 , 220 , 230 , 240 , 255 , 270 , 285 , 300 , 315 , 330 , 340 , 350 , 360 min ) . Blood sample determine FFAs , HbA1c , total- , High Density Lipoprotein ( HDL ) - - , Low Density Lipoprotein ( LDL ) - Very Low Density Lipoprotein ( VLDL ) -cholesterol , triglyceride draw baseline , blood sample measure FFAs insulin-stimulated state draw 240 360 min . Urine sample collect 0 , 120 , 240 360 min . Indirect calorimetry perform basal ( 90-120 min ) , low ( 210-240 min ) high grade ( 330-360 min ) insulin-stimulated steady-state determine oxygen consumption ( V02 ) carbon dioxide production ( VC02 ) . A flow-through canopy gas analyser use , describe ( 25 ) . The average gas exchange three 30-min steady-state period ( basal insulin-stimulated ) use calculate rate glucose fat oxidation . Muscle fat biopsy perform end basal ( t=120 min ) high grade insulin-stimulated ( t=360 min ) steady-state period . Muscle fat biopsy obtain local anaesthesia , musculi vastus lateralis subcutaneous abdominal fat use modify Bergström 's needle ( include suction ) 120 ( basal ) 360 min ( high grade insulin-stimulated ) . Biopsies frozen liquid nitrogen store −80ºC later analysis . The total amount extract tissue amount 400-600 mg .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Moderate severe plaque psoriasis psoriasis area severity index ( PASI ) &gt; 8 ( exclusively patient group ) BMI &lt; 35 kg/m2 Normal fast plasma glucose ( FPG ) 6 mM haemoglobin A1c ( HbA1c ) ≤42 mmol/mol ( 6.0 % ) Normal haemoglobin Informed consent Diabetes ( type 1 type 2 diabetes ) First seconddegree relative diabetes Hormonal contraception Other chronic inflammatory disease Pregnancy breast feed Psychiatric disease Treatment drug might affect glucose metabolism within month prior project Nephropathy ( serum creatinine &gt; 130 µM and/or albuminuria ) Liver disease ( alanine aminotransferase ( ALT ) and/or serum aspartate aminotransferase ( AST ) &gt; 2×normal value )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>